AMT-130

Product

Last mentioned: Mar 3, 2026

Timeline

Jun 30, 2026
Type B FDA Meeting Target

Planned follow-up to define Phase III and regulatory path for AMT-130.
Jun 30, 2026
AMT-260 Data Readout

Expected clinical data from Phase I/IIa epilepsy study in H1 2026.
Mar 2, 2026
Type A FDA Meeting

Discussed AMT-130 approval pathway; alignment not yet reached.
Dec 31, 2025
Fiscal Year End

Closed 2025 with $622.5 million in liquidity.

Stories mentioning AMT-130 1

uniQure Extends Cash Runway to 2029 Amid Ongoing FDA Talks for Huntington's

uniQure reported a strong cash position of $622.5 million, extending its operational runway into 2029. While the company continues to seek regulatory alignment with the FDA for its Huntington’s disease candidate AMT-130, it is advancing clinical trials for epilepsy and Fabry disease with key data readouts expected in 2026.

Mar 3, 2026 2 sources